small mid cap first look
tabl content
small mid cap compani
ndr jame
ndr inc
ndr alexand baldwin
ndr myovant scienc
ndr jame
ndr inc
ndr dover wellsit spin
ndr euronet rayna
ndr alexand baldwin
ndr jame
ndr inc
ndr dover wellsit spin
ndr alexand baldwin
ndr dover wellsit spin
lunch brixmor samir
coverag outperform
small mid cap compani eca iclr
tough sled get easier resum coverag outperform
summari prior acquisit virgin america alaska rightli earn
reput high qualiti airlin strong reliabl custom loyalti high
rel margin sharehold friendli capit return integr virgin
challeng consum importantli compani transit
integr inning back optim support slower growth profil
addit cut year moder growth profil help alaska
begin recov high margin grow free cash flow resum coverag alaska
group outperform rate price target ep base
share
growthtegr high expect ltm share
trail xal airlin index -point -point last year
respect attribut under-perform integr challeng high
street vastli underestim much chang alaska absorb
acquisit virgin potenti chang competit environ
long would take compani get back root level
understand street optim like anchor alaska
reput team earn
compani transit back optim focu integr
agreement move singl reserv system expect april fulli
consum manag time near complet look backward
alaska result also impact effort claim relev
virgin exist custom base believ compani back
core focu -- run high qualiti airlin strong loyalti institution
follow period rapid growth claim virgin custom base alaska
moder growth rate tie-break us effort
relev new california custom base alaska sharpli increas new market
growth last year ad new market california
mani weak season demand period market matur improv
season help unit revenu trend start heal
goal grow free cash flow improv model
capital-expenditure vs compani activ manag free cash
potenti fee alignment/ segment believ compani take
harder look segment unbundl estim million
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
ndr
ndr
lunch jone lang lasal
lunch silverlin privat
opportun healthcar
ndr adama
dinner transocean chmn
opportun per share bring change/ baggag fee in-lin
small mid cap compani summari
pipeston midstream deal phase montney valu realiz
saw eca deliv plan ambiti multi-year develop plan
montney infrastructur requir associ time capit requir
major hurdl field develop much canadian basin three
process plant tower sunris saturn deliv ahead schedul
budget support volum ramp margin uplift
key element invest case eca clear similar structur
midstream agreement pipeston would prioriti sour ga process
hydrogen sulfid carbon dioxid associ sulfur liquid ga higher cost
complex requir unlock higher condens yield associ
pipeston recal end eca struck similar agreement veresen
cn exist infrastructur lever long term agreement
midstream guarante volum return increment capit volum
certainti deal compris entireti dawson ga
gather compress facil plan mm expans
happi outcom agreement suspect templat
today announc acreag dedic revenu guarante reach full
capac today agreement clearli pave way valu realiz
pipeston broader montney eca liquid montney product
come pipeston rig current run sub basin
downgrad
downgrad iclr in-lin due perceiv investor fear headlin risk
biopharma elev absolut valuat versu histor level provid
uninspir risk/reward profil note continu believ iclr manag
team best-in-class among long-term view fundament
remain gener unchang think express conserv view
industri sub-group vs iclr
call larg tactic look risk exposur among life scienc dx tool
gener find downsid risk space bit difficult one would think
strong secular tailwind support growth across geographi end market
howev believ risk tool current take less favor
view complex due mainli headlin issu associ biopharma
sell news overal see uptick biopharma much attent
paid larg custom iclr could lead choppi near-term
book growth could cap multipl expans core assumpt
iclr thesi
iclr lone out-perform group ytd vs flattish
elev valuat rel histori leav us upsid share
current level decent see better entri point come without meaning
capit alloc event open b/ notabl top-lin acceler challeng
see littl room continu multipl expans light biopharma
overhang wait potenti de-rat becom construct share thu
downgrad
downgrad in-lin
downgrad rate in-lin follow today disappoint fda
updat drug activ like prove next ph fda
clarifi amend on-going ph fulfil exactli fda may need
see fda delay compress timelin amidst sever competitor
program make meaning progress depress space result
lower peak sale potenti probabl success
acknowledg model sensit peak sale forecast fulli
own program especi given fix cost base place updat valuat
weight across dcf pe base case forecast assum
risk-adj sale depress also carri risk-adj sale
rest pipelin
daili monitor key event across global luxuri apparel footwear landscap
mall vacanc high
deliveri product figur expect next hr expect
releas deliveri product figur next hour consensu
deliveri expect factset model compani
collect model model
report model product run rate guidanc prior guidanc
model product end unit per week unit per
week report leak e-mail weekend ceo elon musk employe
suggest compani pass unit per week final week quarter
stock march yesterday fall short
weekli product target unit may weigh heavili might
otherwis done particularli given yesterday email leak direct
given market number inde week run-rat short unit
better believ expect clearli show progress vs
compani start year note bloomberg wide follow tracker
suggest run-rat closer unit week
autonom ponder israel
previou coverag mobiley travel israel sever time
past trip particularli special prepar dozen meet
decid re-read start-up nation stori israel econom miracl senor/
singer prime investig one passag struck particularli true
problem israel one command advantag sens purpos
isra may affluenc quiet life affluenc tend
cours three day met broad array excit early-stag
isra ai mobil startup vc govern agenc tel aviv culmin
alway invalu insight prof amnon shashua mobiley hq part
jerusalem meet found team focus/pass constant
remind uniqu isra sens purpos acut describ start-up nation
concept chutzpah question author rosh gadol big pictur think
bitzuist get done rich histori idf elit
militari elit thu fit host michael granoff maniv mobil sit
squar page vc must-read michael list one earliest
american isra auto investor shai agassi better place maniv sinc becom
one israel notabl seed-level mobil vc invest across
av/mobl ecosystem mike clearli man-to-know anyth futur mobil
come israel
initi coverag orthoped industri
part coverag expans initi coverag orthoped sector
includ zimmer biomet ortho sector effect round
coverag larg cap med-tech
host webinar et click
summari industri view ortho sector fundament volum side
improv past year price pressur stabl continu remain level
seen industri also seen share shift within sever categori
net gainer share loser
see key theme shape industri
robot broader adopt continu tailwind given
first mover advantag
cjr bundl valu base care still pilot mode think price
pressur manag
consolid industri still fragment outsid larg joint reconstruct
like see consolid industri structur favor consolid
happen final rule publish close polici chang
medicar advantag part implement requir share
drug rebat patient pharmaci point sale said would consid
respons novemb request inform futur rulemak topic
take provid increment detail might propos
futur year still appear intent requir po rebat point reiter
regulatori author also cite similar propos includ
white hous fiscal budget propos initi rfi like least one
factor prompt recent announc aet would
shift commerci employ risk book po rebat receiv public prais
hh secretari other like follow note plan sponsor
neutral po rebat premium increas econom other along
drug channel dont chang materi either step alon potenti
step toward drug price transpar bear watch also recal hh
secretari said march month administr would roll
whole slate propos lower drug price redirect discount
go middlemen patient instead
happen close post final rate announc
medicar advantag call call increas payment base
propos polici februari advanc notic compar
increas past two year improv driven bp
combin increas cost trend estim plu bp benefit
rebas counti ff cost estim note includ tailwind
anoth one-year moratorium health insur fee upward trend
risk code health plan estim add
reimburs averag
take increment posit rate updat adv plan icare-
focus particular strong improv alreadi high start point
advanc notic includ code trend hif moratorium medicar
advantag reimburs could next year note rebat math reabsorb
hif benefit code trend could less high estim
final rate reinforc administr support stanc toward overal
posit view growth prospect industri particular
see particularli strong setup stand-alone basi takeout option given
report talk altern detail breakdown
rate compon calcul benchmark chang compani
effort gain better understand current state busi upcom
plan equip purchas dentist survey nearli dental practic
second half march gener overal purchas intent total equip
next twelv month histor norm slightli read
howev current total revenu continu improv current level
last quarter read ask
largest impact current revenu dentist said patient volum
economi howev note past quarter increas
number particip begun mention lower insur reimburs
advers impact overal revenu
first time ask dentist use amazon particip
state use amazon least purchas suppli use
amazon averag purchas total suppli websit
ask percentag total suppli expect purchas amazon march
number rose
would like receiv survey go forward let us know email
follow subject pleas add
evrisi compani survey last week increas high
unemploy claim last week declin low
mfg pmi tick still record-high territori
chart qqq set strong
qqq technolog remain strong posit absolut rel buy
 doubl bottom retest critic support remain intact
technolog like odd
fb bullish weekli revers critic support make stock strong buy
bullish revers day make stock trade buy min
remain strong rel absolut trend intact support
bullish weekli revers key support set doubl bottom
upsid
yield yr grind lower fals break-out bund test
crude ralli stiff resist wti/brent stock arent buy
either
ute rather buy ute yield eas crude resist
xlu multi-year support
dollar dxi remain weak usdjpi fight back bullish emfx firm mxn
em pois ralli brazil star em choppi start think
chang
downgrad in-lin
downgrad
research report excerpt herein certifi regul ac secur exchang act analyst primarili
respons said report follow ed hyman rich ross arndt ellinghorst vijay kumar chri mcnalli ross muken michael newshel
umer raffat stephen richardson omar saad jame walsh duan pfennigwerth evercor isi research attest follow view
render research report reflect person view subject compani issuer part compens
directli relat specif recommend view research report
analyst arndt ellinghorst georg gallier chri mcnalli non-u analyst contribut research report non-u analyst
may associ person evercor group therefor regist qualifi nyse finra research analyst
may subject finra rule restrict commun subject compani public appear trade secur
held analyst
